Home >> MARKETPLACE >> FDA expands use of Adcetris

FDA expands use of Adcetris

Print Friendly, PDF & Email

January 2019—The FDA expanded the approved use of Adcetris (brentuximab vedotin) injection in combination with chemotherapy for adult patients with certain types of peripheral T-cell lymphoma. This is the first FDA approval for the treatment of newly diagnosed PTCL.

Adcetris (Seattle Genetics) is a monoclonal antibody that binds to CD30; it is now approved to treat previously untreated systemic anaplastic large cell lymphoma and other CD30-expressing PTCLs in combination with chemotherapy. Adcetris was previously approved by the FDA to treat adult patients with previously untreated stage III or stage IV classical Hodgkin lymphoma, cHL after relapse, cHL after stem cell transplant when a patient is at a high risk of relapse or progression, systemic ALCL after failure of other treatment, and primary cutaneous ALCL or CD30-expressing mycosis fungoides after failure of other treatment.

Seattle Genetics, 425-527-4000

X